Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 15, 2024 (filed on Apr 15, 2024)Insider Name:Wolkin, Harold MortonOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:30 - Acquisition or disposition under a purchase/ownership plan# or value acquired/disposed of:527Price:$8.84
-
Mar 27, 2024 (filed on Mar 28, 2024)Insider Name:Cipher Pharmaceuticals Inc.Ownership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:38 - Redemption, retraction, cancellation, repurchase# or value acquired/disposed of:-25,685Price:$9.17
-
Mar 27, 2024 (filed on Mar 28, 2024)Insider Name:Cipher Pharmaceuticals Inc.Ownership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:38 - Redemption, retraction, cancellation, repurchase# or value acquired/disposed of:25,685Price:$9.17
-
Mar 20, 2024 (filed on Mar 25, 2024)Insider Name:Mailling, RyanOwnership Type:Direct OwnershipSecurities:OptionsNature of Transaction:50 - Grant of options# or value acquired/disposed of:20,000Price:$8.15
-
Mar 20, 2024 (filed on Mar 25, 2024)Insider Name:Mull, CraigOwnership Type:Direct OwnershipSecurities:OptionsNature of Transaction:50 - Grant of options# or value acquired/disposed of:132,575Price:$8.15
-
Mar 20, 2024 (filed on Mar 25, 2024)Insider Name:Jacobs, BryanOwnership Type:Direct OwnershipSecurities:OptionsNature of Transaction:50 - Grant of options# or value acquired/disposed of:50,000Price:$8.15
-
Mar 18, 2024 (filed on Mar 19, 2024)Insider Name:Wolkin, Harold MortonOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:30 - Acquisition or disposition under a purchase/ownership plan# or value acquired/disposed of:606Price:$7.69
-
Feb 16, 2024 (filed on Feb 20, 2024)Insider Name:Wolkin, Harold MortonOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:30 - Acquisition or disposition under a purchase/ownership plan# or value acquired/disposed of:667Price:$6.98
-
Jan 15, 2024 (filed on Jan 18, 2024)Insider Name:Wolkin, Harold MortonOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:30 - Acquisition or disposition under a purchase/ownership plan# or value acquired/disposed of:795Price:$5.86
-
Dec 29, 2023 (filed on Jan 02, 2024)Insider Name:Cipher Pharmaceuticals Inc.Ownership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:38 - Redemption, retraction, cancellation, repurchase# or value acquired/disposed of:-60,372Price:$6.20
Filings by filing date
-
Apr 15, 2024 (filed on Apr 15, 2024)Insider Name:Wolkin, Harold MortonOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:30 - Acquisition or disposition under a purchase/ownership plan# or value acquired/disposed of:527Price:$8.84
-
Mar 27, 2024 (filed on Mar 28, 2024)Insider Name:Cipher Pharmaceuticals Inc.Ownership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:38 - Redemption, retraction, cancellation, repurchase# or value acquired/disposed of:-25,685Price:$9.17
-
Mar 27, 2024 (filed on Mar 28, 2024)Insider Name:Cipher Pharmaceuticals Inc.Ownership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:38 - Redemption, retraction, cancellation, repurchase# or value acquired/disposed of:25,685Price:$9.17
-
Mar 20, 2024 (filed on Mar 25, 2024)Insider Name:Mailling, RyanOwnership Type:Direct OwnershipSecurities:OptionsNature of Transaction:50 - Grant of options# or value acquired/disposed of:20,000Price:$8.15
-
Mar 20, 2024 (filed on Mar 25, 2024)Insider Name:Mull, CraigOwnership Type:Direct OwnershipSecurities:OptionsNature of Transaction:50 - Grant of options# or value acquired/disposed of:132,575Price:$8.15
-
Mar 20, 2024 (filed on Mar 25, 2024)Insider Name:Jacobs, BryanOwnership Type:Direct OwnershipSecurities:OptionsNature of Transaction:50 - Grant of options# or value acquired/disposed of:50,000Price:$8.15
-
Mar 18, 2024 (filed on Mar 19, 2024)Insider Name:Wolkin, Harold MortonOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:30 - Acquisition or disposition under a purchase/ownership plan# or value acquired/disposed of:606Price:$7.69
-
Feb 16, 2024 (filed on Feb 20, 2024)Insider Name:Wolkin, Harold MortonOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:30 - Acquisition or disposition under a purchase/ownership plan# or value acquired/disposed of:667Price:$6.98
-
Jan 15, 2024 (filed on Jan 18, 2024)Insider Name:Wolkin, Harold MortonOwnership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:30 - Acquisition or disposition under a purchase/ownership plan# or value acquired/disposed of:795Price:$5.86
-
Dec 29, 2023 (filed on Jan 02, 2024)Insider Name:Cipher Pharmaceuticals Inc.Ownership Type:Direct OwnershipSecurities:Common SharesNature of Transaction:38 - Redemption, retraction, cancellation, repurchase# or value acquired/disposed of:-60,372Price:$6.20
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
Company Contact | |
Address: | 5750 Explorer Drive,, Suite 404 MISSISSAUGA ON L4W 0A9 |
Tel: | N/A |
Website: | https://www.cipherpharma.com |
IR: | See website |
Key People | ||
Craig J. Mull Chairman of the Board, Interim Chief Executive Officer | Bryan Jacobs Chief Financial Officer | Diane Gajewczyk Vice President - Scientific and Medical Affairs |
Business Overview |
Cipher Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the United States and South America. Its Dermatology products include Actikerall, Epuris, Ozanex and Vaniqa. Its Hospital Acute Care products include Aggrastat and Brinavess. Its Out-Licensed products include Absorica, ConZip and Lipofen. The Company is also focused on building a portfolio of prescription medicines that serve unmet medical needs. The Company's product pipeline development programs including MOB-015, DTR-001, and CF-101. The Company's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC, and Cipher Pharmaceuticals US LLC. |
Financial Overview |
For the fiscal year ended 31 December 2023, Cipher Pharmaceuticals Inc revenues increased 2% to $21.2M. Net income decreased 23% to $20.4M. Revenues reflect Licensing revenue increase of 4% to $8.5M, Product revenue increase of 1% to $12.7M. Net income was offset by Research and development increase of 42% to $139K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from $1.05 to $0.82. |
Employees: | 6 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $152.03M as of Dec 31, 2023 |
Annual revenue (TTM): | $29.07M as of Dec 31, 2023 |
EBITDA (TTM): | $15.47M as of Dec 31, 2023 |
Net annual income (TTM): | $28.00M as of Dec 31, 2023 |
Free cash flow (TTM): | $21.78M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 24,107,316 as of Apr 12, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |